A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder.

Menchón, José M; Real, Eva; Alonso, Pino; Aparicio, Marco Alberto; Segalas, Cinto; Plans, Gerard; Luyten, Laura; Brunfaut, Els; Matthijs, Laurean; Raymakers, Simon; Bervoets, Chris; Higueras, Antonio; Katati, Majed; Guerrero, José; Hurtado, Mariena; Prieto, Mercedes; Stieglitz, Lennart H; Löffelholz, Georg; Walther, Sebastian; Pollo, Claudio; ... (2021). A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder. Molecular psychiatry, 26(4), pp. 1234-1247. Nature Publishing Group 10.1038/s41380-019-0562-6

Preview

Text s41380-019-0562-6.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (3MB) | Preview

Deep brain stimulation (DBS) has been proposed for severe, chronic, treatment-refractory obsessive-compulsive disorder (OCD) patients. Although serious adverse events can occur, only a few studies report on the safety profile of DBS for psychiatric disorders. In a prospective, open-label, interventional multi-center study, we examined the safety and efficacy of electrical stimulation in 30 patients with DBS electrodes bilaterally implanted in the anterior limb of the internal capsule. Safety, efficacy, and functionality assessments were performed at 3, 6, and 12 months post implant. An independent Clinical Events Committee classified and coded all adverse events (AEs) according to EN ISO14155:2011. All patients experienced AEs (195 in total), with the majority of these being mild (52% of all AEs) or moderate (37%). Median time to resolution was 22 days for all AEs and the etiology with the highest AE incidence was 'programming/stimulation' (in 26 patients), followed by 'New illness, injury, condition' (13 patients) and 'pre-existing condition, worsening or exacerbation' (11 patients). Sixteen patients reported a total of 36 serious AEs (eight of them in one single patient), mainly transient anxiety and affective symptoms worsening (20 SAEs). Regarding efficacy measures, Y-BOCS reduction was 42% at 12 months and the responder rate was 60%. Improvements in GAF, CGI, and EuroQol-5D index scores were also observed. In sum, although some severe AEs occurred, most AEs were mild or moderate, transient and related to programming/stimulation and tended to resolve by adjustment of stimulation. In a severely treatment-resistant population, this open-label study supports that the potential benefits outweigh the potential risks of DBS.

Interest & Impact

Downloads

245 since deposited on 04 Nov 2019
18 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item